The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Level 2 - randomized trial
Secondary correlational analysis of a randomized dose-ranging trial
PubMed 39706482 · doi:10.1016/j.jad.2024.12.061
What was done
Exploratory correlation analysis of a trial in which 233 participants with treatment-resistant depression received a single dose of COMP360 psilocybin (25 mg, 10 mg, or 1 mg) with psychological support. The acute psychedelic experience was measured using the Five-Dimensional Altered States of Consciousness questionnaire (5D-ASC) and the Emotional Breakthrough Inventory (EBI). These measures were correlated with changes in depression severity on the Montgomery-Åsberg Depression Rating Scale (MADRS) at 3 weeks post-administration.
What was found
Mean intensity of psychedelic effects was dose-dependent, though score distributions overlapped considerably across dose tiers. Depressive symptom improvement correlated with specific acute experiential dimensions. In the 25 mg cohort, Week 3 MADRS score reductions correlated most strongly with the Emotional Breakthrough Inventory (r = -0.637), 5D-ASC Visual Restructuralization (r = -0.516), and 5D-ASC Oceanic Boundlessness (r = -0.508).
Why it matters
These results suggest that the subjective quality and depth of acute emotional and psychedelic experiences are linked to psilocybin's therapeutic antidepressant effect rather than being incidental side effects.
Limits
Correlational analyses cannot establish whether subjective psychedelic experiences causally produce therapeutic benefit or merely reflect pharmacodynamic exposure. Findings are exploratory, outcomes are reported only up to 3 weeks post-treatment, and the formulation was evaluated in a sponsor-developed trial.
Cited by
- supports Emotional release during psychedelic sessions is a key factor predicting positive clinical outcomes.